January 5, 2017
Presenting for the second consecutive year, Quanterix will be kicking off the 2017 conference by highlighting the Company’s position to transform precision health
Quanterix to Unveil Groundbreaking Neurodegenerative Disease Research and Strategic Partnership at Neuroscience 2016
November 15, 2016
Researchers will present key findings on the development of sensitive predictive biomarkers to establish therapeutic strategies for neurodegenerative diseases; Company will join forces with UmanDiagnostics to provide an ultrasensitive assay for Nf-L
November 3, 2016
Following the Company's successful participation in the Powering Precision Health Summit, Quanterix is bringing its insights and innovations to the West Coast
October 18, 2016
Quanterix announces that it has been named the “Late Stage Leader” Buzz of BIO winner. As a winner of this award – which recognizes innovative companies that have raised more than $25 million as of July 1, 2016 – Quanterix will also be presenting at the 2016 BIO Investor Forum.
September 26, 2016
Quanterix announces that it is making a strategic investment in ImmunArray, a molecular diagnostics company advancing the development of novel, multi-marker tests for complex diseases with compelling levels of accuracy.
Quanterix and Illumina Founder to Present Novel Approach to Cancer Diagnostics at Powering Precision Health 2016
September 21, 2016
August 1, 2016
Quanterix announces a license agreement for research use with Banyan Biomarkers, a pioneering company in the development of biomarkers for traumatic brain injury (TBI).
Frontage Laboratories Announces Partnership with Quanterix and Validation of Simoa HD-1 Analyzer and Software to Support Biomarker Analysis
June 15, 2016
Frontage Laboratories, Inc., a Contract Research Organization based in Pennsylvania, New Jersey and China, announces that they are the first CRO to complete a GLP validation of the Simoa HD-1 Analyzer and software along with the interface to Watson LIMS.
May 24, 2016
Quanterix announces that the Company’s CEO and Executive Chairman, Kevin Hrusovsky, will be presenting at the 5th Annual One Mind Summit.
Quanterix Opens Call for Proposals for Second Annual Accelerator Grant Program Focused on Oncology and Liquid Tumor Biopsy Technology
April 18, 2016
Quanterix announces the recipient of its first annual Accelerator Grant Program and a call for proposals for its second grant, focused on oncology research. The state-of-the-art Simoa Accelerator Lab is a dedicated laboratory environment for custom assay development and clinical sample testing.